期刊文献+

富含T细胞表位的肿瘤成纤维细胞激活蛋白片段克隆表达及纯化

Cloning expression and purification of the polypeptide with abundant T cell epitopes from tumor fibroblast activation protein
原文传递
导出
摘要 目的:表达并纯化富含T细胞表位的肿瘤成纤维细胞激活蛋白(fibroblas tactivation protein,FAP)片段。方法:利用T细胞表位预测软件及酶切位点预测软件分析FAP全长,选取FAP蛋白内富含T细胞表位又缺少酶切位点的多肽AA264~AA449(NP-032012.1)作为目的表达片段。该多肽所对应的核酸片段为mRNA798~1418(GenBank:BC019190.1)。利用PCR技术从含有FAP基因全长的质粒pCDNA3.1-FAP中扩增目的基因mRNA798~1418,并将该基因与原核表达载体pET-28a(+)连接,在BL21工程菌中实现重组蛋白His6-FAP的表达,并利用His标签进行纯化。结果:成功构建了富含T细胞表位的FAP原核表达质粒pET-28a(+)-FAP对该质粒进行BamHl/Xhol双酶切鉴定,鉴定结果与预期完全一致;实现了对该质粒编码的融合蛋白His6-FAP2的表达,表达后的融合蛋白主要以包涵体的形式存在;利用His标签纯化了该融合蛋白,纯化后灰度分析其纯度达95%。结论:成功表达并纯化了富舍细胞表位的FAP片段,为下一步以FAP为靶标的肿瘤免疫治疗策略提供了实验基础。 OBJECTIVE:To express and purify the tumor fibroblast activation protein (FAP) fragment enriched T cell epitopes. METHODS: Amino acid sequence of FAP was analysed by SYFPEITHI software combined with PAProC software,and then target fragment AA264-AA449 (NP_032012.1) with abundant T cell epitopes and lack of cleavage sites of protease were selected. The corresponding target gene for the polypeptide was mRNA798-1418 (GenBank: BC019190.1). Gene fragment mRNA798-1418 was amplified from pCDNA3.1-FAP by PCR and cloned into pET 28a(+ ) vector,the recombinant protein His6-FAP264-449 was expressed in BL21 engineering bacteria and then purified by His tag. RESULTS: The prokaryotic expression plasmid of FAP with abundant T cell epitopes was successfully constructed,and the results identified by double digestion with BamH1/Xhol corresponded exactly well as expected. The fusion protein His6-FAP264-449 was expressed and mainly existed in the form of inclusion body. Then the fusion protein was purified,its purity reached 95% through the gray-scale analysis. CONCLUSION: The FAP fragment enriched T cell epitopes was ex- pressed and purified successfully,that provided a basis for tumor immunotherapy targeting FAP.
出处 《中华肿瘤防治杂志》 CAS 北大核心 2014年第1期1-4,共4页 Chinese Journal of Cancer Prevention and Treatment
基金 国家自然科学基金(81201763) 广东医学院科研基金(B2010001)
关键词 肿瘤 T细胞表位 成纤维细胞激活蛋白 原核表达 纯化 neoplasms T cell epitope fibroblast activation protein prokaryotic expression purification
  • 相关文献

参考文献13

  • 1Fidler IJ.The pathogenesis of cancer metastasis:The seed andsoil hypothesis revisited[J].Nat Rev Cancer,2003,3(6):453-458.
  • 2Mueller MM,Fusenig NE.Friends or foes-bipolar effects of thetumor stroma in cancer[J].Nat Rev Cancer,2004,4(11):839-849.
  • 3Hwang RF,Moore T,Arumugam T,et al.Cancer associated stromalfibroblasts promote pancreatic tumor progression[J].Cancer Res,2008,68(3):918-926.
  • 4Obrien P,Oconnor BF.Seprase:an overview of an important ma-trix serine protease[J].Biochim Biophys Acta,2008,1784(9):1130-1145.
  • 5Monsky W,Lin C,Aoyama A,et al.A potential marker proteaseof invasiveness,separase,is localized on invadopodia of humanmalignant melanoma cells[J].Cancer Res,1994,54(21):5702-5710.
  • 6Park J,Lenter M,Zimmermann R,et al.Fibroblast activation protein,a dual specificity serine protease expressed in reactive human tumorstromal fibroblasts[J].J Biol Chem,1999,274(51):36505-36512.
  • 7Nussbaum A,Kuttler C, Tenzer S,et al.Using the world wideweb for predicting CTL epitopes[J].Curr Opin Immunol,2003,15(1):69-74.
  • 8Angelica S,Jason J,Nazneen A,et al.Targeting fibroblast activa-tion protein inhibits tumor stromagenesis and growth in mice[J].J Clin Invest,2009,119(12):3613-3625.
  • 9Matthew K,Paul J,Bambrough,et al.Suppression of antitumorimmunity by stromal cells expressing fibroblast activation pro-tein-a[J].Science,2010^330(6005):827-830.
  • 10Loeffler M,Krger J,Niethammer A,et al.Targeting tumor-asso-ciated fibroblasts improves cancer chemotherapy by increasingintratumoral drug uptake[J].J Clin Invest,2006,116(7):1955-1962.

二级参考文献11

  • 1Mueller M M, Fusenig N E. Friends or foes-bipolar effects of the tumour stroma in cancer[J]. Nature Reviews, 2004, 4(11) : 839- 849.
  • 2Chen W T, Kelly T. Seprase complexes in cellular invasiveness [J]. Cancer Metastasis Reviews, 2003, 22(2 -3):259 -269.
  • 3Ghersi G, Dong H, Goldstein L A, et al. Regulation of fibroblast migration on collagenous matrix by a cell surface peptidase complex[J]. J Biol Chem, 2002, 277(32): 29231-29241.
  • 4Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan,fluorouracil, and leucovorin for metastatic color eetalcancer[J]. N Engl J Med, 2004, 350(23): 2335 -2342.
  • 5Cheng J D, Weiner L M. Tumors and their microenvironments: tilling the soil[J].Clin Cancer Res, 2003, 9(5) : 1590-1595.
  • 6Cheng J D, Valianou M, Canutescu A A, et al. Abrogation of fibroblast activation protein enzymatic activity attenuates tumor growth[J]. Mol Cancer Ther, 2005, 4(3): 351-360.
  • 7Loeffler M, Kruger J A, Niethammer A G, et al. Targeting tumorassociated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake[J]. J Clin Invest, 2006, 116 (7): 1955- 1962.
  • 8Cohen M H, Gootenberg J, Keegan P, et al. FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer[J]. Oncologist, 2007, 12(3) : 356-361.
  • 9Giusti R M, Shastri K A, Cohen M H, et al. FDA drug approval summary: panitumumab (Vectibix)[J]. Oncologist, 2007, 12(5):577-583.
  • 10Hudis C A. Trastuzumab-mechanism of action and use in clinical practice[J]. N Engl J Med,2007, 357(1): 39-51.

共引文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部